Controlled Human Malaria Infection by Intradermal Injection of Plasmodium Falciparum Sporozoites in Tanzanian Adults

NCT ID: NCT01540903

Last Updated: 2014-09-10

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 30 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2012-02-29
• Study Completion Date: 2013-08-31

Brief Summary

The proposed trial will evaluate whether relatively non immune populations in endemic countries can be effectively infected with aseptic, purified, cryopreserved sporozoites (PfSPZ Challenge) given intradermally.

Detailed Description

Controlled human malaria infection (CHMI) is a critical component of malaria vaccine and drug development and is an important element of any strategy for accelerating the development of new tools for malaria control, elimination and eradication. Until now, CHMI has been performed in malaria naïve subjects from countries not endemic for malaria using both infectious mosquitoes and recently, aseptic, purified, cryopreserved Plasmodium falciparum sporozoites (PfSPZ). Results from these studies report significant infection success in all study subjects and an excellent safety profile.

The conduct of CHMI studies in malaria endemic populations will allow early understanding of responses to new vaccines and drugs in endemic country populations and for direct comparisons between previously exposed and non-exposed individuals. Performing CHMI studies in malaria endemic countries will reduce associated costs, speed-up the process of testing and substantially contribute to the acceleration of the malaria vaccine and drug research and development processes.

This study to be conducted in Bagamoyo, Tanzania, aims to see whether people in endemic countries with minimal previous history of malaria are suitable for CHMI using PfSPZ Challenge. This study will also assess whether the success rate of the experiment is improved by lowering the volume of injection and increasing the number of inoculations. Hence, the study will contribute towards improvements in the CHMI studies using syringe and needle inoculation of sporozoites.

Conditions

Malaria

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: DIAGNOSTIC
• Blinding Strategy: DOUBLE

Study Groups

Group 1 10,000 PfSPZ

12 volunteers, ID PfSPZ Challenge total dose 10,000 PfSPZ administered by 2 injections of 50µL each.

Group Type: EXPERIMENTAL

PfSPZ Challenge

Intervention Type: BIOLOGICAL

Aseptic, purified, vialed, cryopreserved, fully infectious NF54 Plasmodium falciparum sporozoites (PfSPZ Challenge)

Group 2 25,000 PfSPZ

12 volunteers, ID PfSPZ Challenge total dose 25,000 PfSPZ administered in 4 injections of 10µL each.

Group Type: EXPERIMENTAL

PfSPZ Challenge

Intervention Type: BIOLOGICAL

Aseptic, purified, vialed, cryopreserved, fully infectious NF54 Plasmodium falciparum sporozoites (PfSPZ Challenge)

Controls - saline

4 Volunteers, ID saline administered in 2 injections of 50µL each and 2 volunteers, ID saline administered in 4 injections of 10µL each.

Group Type: PLACEBO_COMPARATOR

Saline

Intervention Type: BIOLOGICAL

Saline

Interventions

PfSPZ Challenge

Aseptic, purified, vialed, cryopreserved, fully infectious NF54 Plasmodium falciparum sporozoites (PfSPZ Challenge)

Intervention Type: BIOLOGICAL

Saline

Saline

Intervention Type: BIOLOGICAL

Other Intervention Names

Plasmodium falciparum sporozoites

Eligibility Criteria

Inclusion Criteria

• Healthy Male aged between 20-35 years, healthy volunteers
• Good Health status based on history & clinical examination
• Residing in or near DaresSalaam
• Willing to contribute to science in Tanzania
• Free from malaria parasite by blood smear & qRT-PCR
• Not suffering from any chronic illness including HIV/AIDS
• No documented history of malaria infection for the past 5 yrs
• Able & willing to come for complete one year follow up including minimum of three weeks of hospitalization
• All volunteers must sign the informed consent form & answer correctly 15 out 15 questions demonstrating their understanding of the meaning & procedures of the study
• Volunteer agrees to inform study doctor & agrees to release medical information concerning contra-indications for participation in the study
• Living with a third party that will contact the study team if in case of alteration of consciousness during the first month of the study
• Willing to undergo a Pf sporozoite challenge.
• Willing to take curative treatment for malaria (Coartem®) & any other medication which may be prescribed by a study doctor during study period
• All volunteers agree to stay in the hospital during parts of the study (overnight after challenge, up to 15 days during follow up & 3 days of Coartem® treatment)
• Reachable (24/7) by mobile phone during the whole study period
• Agreement not to participate in another study during the study period.
• Agreement not to donate blood during the study period.
• Available to attend all study visits
• Willingness to undergo HIV, hepatitis B & hepatitis C tests

Exclusion Criteria

• History of malaria in the past 5 yrs
• Plans to travel outside the Dar-es-salaam or Coast Region in first month (day 0-28) of the study
• Plans to travel to highly malarious areas in the 6 months following the study period
• Previous participation in malaria vaccine study &/or positive serology for Plasmodium falciparum asexual crude extract antibodies above acceptable cut off established for the site.
• History of arrhythmias or prolonged QT-interval or other cardiac disease
• Positive family history of in the 1st & 2nd degree relative for cardiac disease <50 yrs old.
• Volunteers unable to read & write in English & give written informed consent
• Previous history of drug or alcohol abuse interfering with normal social function
• A history of psychiatric disease
• The use of chronic immunosuppressive drugs, antibiotics, or other immune modifying drugs within three months of study onset (inhaled & topical corticosteroids are allowed) & during the study period
• A history or confirmed sickle cell anemia, sickle cell trait, thalassemia , thalassemia trait or G6PD deficiency
• Co-worker of the Ifakara Health Institute
• Symptoms, physical signs & laboratory values suggestive of systemic disorders including renal, hepatic, cardiovascular, pulmonary, skin, immunodeficiency, psychiatric, & other conditions which could interfere with the interpretation of the study results or compromise the health of the volunteers
• History of diabetes mellitus or cancer
• An estimated, ten year risk of fatal cardiovascular disease of <5%, as estimated by the Systematic Coronary Risk Evaluation (SCORE) system
• Clinically significant abnormalities in electrocardiogram at screening
• Body Mass Index below 18 or above 30kg/m2
• Any clinically significant deviation from the normal range in biochemistry or hematology blood tests or in urine analysis or electrolytes
• Positive HIV, Hepatitis B virus or Hepatitis C Virus tests
• Participation in any other clinical study within 30 days prior to the onset of the study or during the study period
• Volunteers unable to be closely followed for social, geographic or psychological reasons
• Known hypersensitivity of other contra-indications to Coaterm® or Malarone® including treatment taken by the volunteer that interferes with Coartem® or Malarone®
• Any confirmed or suspected immunosuppressive or immunodeficient condition, including asplenia

• Minimum Eligible Age: 20 Years
• Maximum Eligible Age: 35 Years
• Eligible Sex: MALE
• Accepts Healthy Volunteers: Yes

Sponsors

Ifakara Health Research and Development Centre

OTHER

Sponsor Role: collaborator

Swiss Tropical & Public Health Institute

OTHER

Sponsor Role: collaborator

Sanaria Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Salim Abdulla, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Ifakara Health Institute (IHI), Tanzania

Locations

Bagamoyo Research and Training Center, Ifakara Health Institute

Bagamoyo, , Tanzania

Countries

Tanzania

References

Shekalaghe S, Rutaihwa M, Billingsley PF, Chemba M, Daubenberger CA, James ER, Mpina M, Ali Juma O, Schindler T, Huber E, Gunasekera A, Manoj A, Simon B, Saverino E, Church LWP, Hermsen CC, Sauerwein RW, Plowe C, Venkatesan M, Sasi P, Lweno O, Mutani P, Hamad A, Mohammed A, Urassa A, Mzee T, Padilla D, Ruben A, Sim BKL, Tanner M, Abdulla S, Hoffman SL. Controlled human malaria infection of Tanzanians by intradermal injection of aseptic, purified, cryopreserved Plasmodium falciparum sporozoites. Am J Trop Med Hyg. 2014 Sep;91(3):471-480. doi: 10.4269/ajtmh.14-0119. Epub 2014 Jul 28.

Reference Type: RESULT

PMID: 25070995 (View on PubMed)

Other Identifiers

BSPZC1

Identifier Type: -

Identifier Source: org_study_id